Entrada Therapeutics, Inc.

Listed Company

TRDACIK 0001689375NasdaqEmerging GrowthPharmaceutical PreparationsDelawareFY ends Dec 31

Period

FY 2025

Revenue

$25.42M

Net Income

$-143.75M

Total Assets

$377.38M

Equity

$306.13M

Shares Out

38.28M

Op. Cash Flow

$-128.51M

Business

Entrada Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing intracellular therapeutics using its proprietary endosomal escape (EEV) delivery platform. It is developing EEV-conjugated oligonucleotide therapies (EEV‑PMOs) targeting exon‑specific Duchenne muscular dystrophy candidates (ENTR‑601‑44, ‑45, ‑50, ‑51), a partnered DM1 candidate (VX‑670) with Vertex, and ocular and other preclinical programs. Its key business segments include a neuromuscular franchise, a strategic collaboration with Vertex, and discovery/preclinical platform programs spanning enzyme/protein, gene editing, LNP and CNS/PNS opportunities. The company conducts global clinical and regulatory activities across the United States, United Kingdom, Europe and other jurisdictions and relies on third‑party CMOs and clinical sites for development and supply.

Summary from filing dated 2025-02-27

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Collaboration revenue	25	211	129	—	—
Research and development	142	125	100	67	36
General and administrative	41	38	32	31	15
Total operating expenses	183	164	132	97	51
(Loss) income from operations	−158	47	−3	−97	−51
Interest and other income	15	19	15	3	−31,000
Total other income	15	19	15	3	−31,000
(Loss) income before provision for income taxes	−143	67	12	−95	—
Total income tax provision	900,000	900,000	−19	0	—
Net (loss) income	−144	66	−7	−95	−51
Net (loss) income per share, basic (in dollars per share)	−3.47	1.76	−0.2	−3.02	−8.16
Net (loss) income per share, diluted (in dollars per share)	−3.47	1.68	−0.2	−3.02	−8.16
Weighted-average common shares outstanding, basic (in shares)	41	37	33	31	6
Weighted-average common shares outstanding, diluted (in shares)	41	39	33	31	6
Unrealized gain (loss) on marketable securities, net of tax of $0	695,000	−238,000	2	—	—
Total other comprehensive income (loss)	695,000	−238,000	2	−2	0
Total comprehensive (loss) income	−143	65	−4	−97	−51

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	90	101	68	45	291
Marketable securities	205	319	284	144	0
Restricted cash, current portion	658,000	0	—	—	—
Collaboration receivable	1	4	6	0	—
Prepaid expenses and other current assets	9	16	12	21	8
Total current assets	306	440	370	210	299
Property and equipment, net	7	11	11	8	6
Restricted cash, net of current portion	3	4	4	4	0
Right-of-use assets, operating leases	60	71	81	25	—
Other non-current assets	70,000	284,000	3	5	872,000
Total assets	377	526	469	252	306
Accounts payable	2	4	3	6	706,000
Accrued expenses and other current liabilities	18	13	11	8	6
Income taxes payable	0	667,000	4	0	—
Operating lease obligations, current portion	4	8	8	8	0
Deferred revenue, current portion	342,000	14	132	0	—
Total current liabilities	24	39	159	22	7
Operating lease obligations, net of current portion	47	52	60	18	—
Deferred revenue, net of current portion	0	7	8	0	—
Total liabilities	71	98	227	40	7
Commitments and contingencies (Note 10)	—	—	—	—	—
Common stock, par value $0.0001; 150,000,000 shares authorized; 38,284,221 shares issued and outstanding as of December 31, 2025 and 37,585,944 shares issued and 37,574,538 shares outstanding as of December 31, 2024	4,000	4,000	3,000	3,000	3,000
Additional paid-in capital	579	558	437	403	392
Accumulated other comprehensive income (loss)	652,000	−43,000	195,000	−2	0
Accumulated deficit	−273	−129	−195	−188	−94
Total stockholders equity	306	429	242	213	299
Total liabilities and stockholders equity	377	526	469	252	306

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Net (Loss) income	−144	66	−7	−95	−51
Depreciation expense	4	4	3	2	1
Stock-based compensation expense	20	18	13	10	3
Net amortization of premium (accretion of discount) on marketable securities	−4	−10	−6	151,000	0
Collaboration receivable	3	2	−6	0	—
Prepaid expenses and other current assets	8	−4	9	−14	−7
Right-of-use assets, operating leases	11	10	12	8	—
Other non-current assets	214,000	3	−12	−4	−331,000
Accounts payable	−2	991,000	−3	5	−715,000
Accrued expenses and other current liabilities	5	2	4	2	4
Income taxes payable	−667,000	−3	4	0	—
Deferred revenue	−20	−120	140	0	—
Operating lease liabilities	−8	−9	−12	−7	—
Net cash used in operating activities	−129	−42	140	−94	−51
Purchases of property and equipment	−1	−3	−6	−3	−5
Purchases of marketable securities	−142	−438	−407	−222	0
Maturities of marketable securities	259	413	274	76	0
Net cash provided by (used in) investing activities	117	−28	−138	−149	−5
Proceeds from exercise of stock options	425,000	3	443,000	284,000	410,000
Proceeds from issuance of common stock under the employee stock purchase plan	462,000	574,000	443,000	—	—
Net cash provided by financing activities	887,000	103	21	479,000	307
Net (decrease) increase in cash, cash equivalents and restricted cash	−11	34	22	−242	252
Purchases of property and equipment included in accounts payable and accrued expenses	0	560,000	208,000	88,000	155,000
Vesting of options early exercised subject to repurchase	14,000	51,000	91,000	135,000	250,000
Cash paid for income taxes	2	5	15	0	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro